Long-term follow-up on AL-001 eye injection for wet macular degeneration
A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
This study is looking to see how safe and effective the AL-001 eye injection is for people with wet macular degeneration over a long period of time after they’ve already had it once before.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 21 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Beijing Anlong Biopharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06718816 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term safety and efficacy of AL-001 ophthalmic injection administered via suprachoroidal space in patients with wet age-related macular degeneration (wAMD). Participants must have previously received a single dose of AL-001 in an earlier clinical study. The study will involve regular follow-up visits to monitor the outcomes and any potential side effects associated with the treatment. The focus is on gathering data to better understand the long-term effects of this innovative injection method.
Who should consider this trial
Good fit: Ideal candidates are individuals who have previously participated in a study involving AL-001 and received the injection.
Not a fit: Patients who have not previously received AL-001 or those who do not meet the inclusion criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of AL-001 for patients suffering from wAMD.
How similar studies have performed: While this specific approach is observational, similar studies evaluating long-term effects of ophthalmic injections have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection. * The subject or their legal representative agrees to participate in this study and signs a written ICF. * The subjects are willing and able to follow planned visits and procedures. Exclusion Criteria: * None
Where this trial is running
Beijing, Beijing Municipality
- Chinese Academy of Medical Sciences & Peking Union Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: AnlongBio
- Email: info@anlongbio.com
- Phone: +86-010-80414166
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.